logo

 

MIRA INFORM REPORT

 

 

Report Date :

09.04.2011

 

IDENTIFICATION DETAILS

 

Name :

AJANTA PHARMA LIMITED

 

 

Registered Office :

Ajanta House 98 Government Industrial, Area Charkop, Kandivli (West), Mumbai-400067

 

 

Country :

India

 

 

Financials (as on) :

31.03.2010

 

 

Date of Incorporation :

31.12.1979

 

 

Com. Reg. No.:

11-22059

 

 

CIN No.:

[Company Identification No.]

L24230MH1979PLC022059

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMA08396D/MUMA19462C

 

 

PAN No.:

[Permanent Account No.]

AAACA5579P

 

 

Legal Form :

Public Limited Liability Company. The company’s Shares are listed on the stock exchange.

 

 

Line of Business :

Manufacturer and Exporter of Pharmaceutical Products in the form of Tablets, Capsules, Liquids, Injectables, Powders and Others.

 

 

RATING & COMMENTS

 

MIRA’s Rating :

A (62)

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

Maximum Credit Limit :

USD 7036272

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well established and reputed company having fine track. Financial position of the company appears to be sound. Trade relations are reported as fair. Payments are reported to be regular and as per commitments.

 

The company can be considered good for normal business dealings at usual trade terms and conditions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – April 1, 2010

 

Country Name

Previous Rating

(31.12.2009)

Current Rating

(01.04.2010)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INFORMATION PARTED BY

 

Note - Management non-cooperative name not disclosed

 

LOCATIONS

 

Registered Office / Factory – I :

Ajanta House 98 Government Industrial, Area Charkop, Kandivli (West), Mumbai-400067, India

Tel. No.

91-22-66061000

Fax No.

91-22-66061200/1300

E-Mail

info@ajantapharma.com

Website

http://www.ajantapharma.com

 

 

Factory-2 :

B-4, B-5, B-6 MIDC Industrial Area, Paithan, Aurangabad-431128, Maharashtra

Tel. No.:

91-2431-233092

Fax No.:

91-2431-232088

 

 

Factory-3 :

31-O, MIDC Industrial Area, Chikalthana, Aurangabad-431210, Maharashtra, India

Tel. No.:

91-240-22485851

Fax No.:

91-240-22485850

 

 

Factory-4 :

Gut No. 11/12/14/15, Chitegaon, Paithan, Road, Aurangabad-431 105, Maharashtra, India

 

 

Factory -5 :

Gut No. 378, Plot No. 8, Waluj, Aurangabad, Maharashtra, India

 

 

Factory-6 :

43 AB & 44BCD, ADVENT, Charkop, Kandivli (W), Mumbai – 400 067, Maharashtra, India

 

 

DIRECTORS

 

Name :

Mr. Mannalal B. Agrawal

Designation :

Chairman

 

 

Name :

Mr. Purushottam B. Agrawal

Designation :

Vice Chairman

 

 

Name :

Mr. Madhusudan B. Agrawal

Designation :

Vice Chairman

 

 

Name :

Mr. Yogesh M. Agrawal

Designation :

Managing Director

 

 

Name :

Dr. Anil Kumar

Designation :

Director

 

 

Name :

Mr. Chandrakant M. Khetan

Designation :

Director

 

 

Name :

Mr. Subal Chandra Saha

Designation :

Nominee Director (IDBI Bank)

 

 

Name :

Ms. Manjiri Bhalerao

Designation :

Nominee Director (Exim Bank)

 

 

KEY EXECUTIVES

 

Name :

Mr. Nikhil Bhatt

Designation :

Company Secretary

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 31.12.2010

 

Names of Shareholders

No. of Shares

Percentage of Holding

(A) Shareholding of promoters and Promoter Group

 

 

1. Indian

 

 

Individuals / Hindu Undivided Family

7424691

63.41

Bodies Corporate

398930

3.41

 

 

 

(B) Public Shareholding

 

 

1. Institutions

 

 

Financial Institutions  / Banks

2940

0.03

Foreign Institutional Investors

2500

0.02

Any Other (Specify)

 

 

Trusts

100

--

 

2. Non Institutions

 

 

Bodies Corporate

861272

7.36

Individual shareholders holding nominal share capital up to Rs. 0.100 million

2173531

18.56

Individual shareholders holding nominal share capital in excess of Rs. 0.100 million

761804

6.51

 

 

 

Any Other Specify

 

 

Clearing Members

23153

0.20

Market Maker

12593

0.11

Non Resident Indians

30190

0.26

Hindu Undivided Families

16796

0.14

 

 

 

Shares held by custodians and against which depository receipts have been issued  (C)

--

--

 

 

 

Total (A) + (B) +(C)

11708500

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer and Exporter of Pharmaceutical Products in the form of Tablets, Capsules, Liquids, Injectables, Powders and Others.

 

 

Products :

Product Description

Item Code No.

(As per ITC Code)

Anti-Malarial Preparations (Artfan)

30049049

Erectile Dysfunction Preparations (Kamagra)

30049099

Dermatology Preparations (Melacare)

30043913

 

 

PRODUCTION STATUS AS ON 31.03.2010

 

Particulars

Unit

Installed Capacity

Tablets

Million Nos

1500

Capsules

Million Nos

425

Liquids

Million Nos

8

Powder

Million Nos

21

API

Tonnes

18

 

 

GENERAL INFORMATION

 

No. of Employees :

600 (Approximately)

 

 

Bankers :

  • Bank of India

 

 

Facilities :

 

Secured Loan

 

Rs. In Millions

31.03.2010

Rs. In Millions

31.03.2009

Term Loans from Banks/Institutions

 

 

Rupee Loan

1193.784

1045.345

Foreign Currency Loan

4.770

26.940

 

 

 

Working Capital Loans from Banks/Institutions

 

 

Rupee Loan

163.015

903.457

Foreign Currency Loan

446.295

25.277

 

 

 

Other Loans – Rupee Loan

7.380

7.539

Total

1815.244

2008.558

 

Notes

 

(i) Term loans are secured by first charge on all fixed assets of the company and second charge on entire current assets of the company, present & future on pari passu basis in addition to personal guarantee of some of the directors.

 

(ii) Working capital loans are secured by first charge on all current assets of the company and second charge on fixed assets of the company on pari passu basis in additions to the personal guarantee of some of the directors.

 

(iii) Other loans are secured against vehicles acquired under the scheme.

 

 

 

 

Unsecured Loan

 

Rs. In Millions

31.03.2010

Rs. In Millions

31.03.2009

Deferred Sales Tax Liabilities

86.108

73.482

Others Loans

131.557

320.179

 

 

 

Total

217.665

393.661

 

 

 

Banking Relations :

---

 

 

Auditors :

 

Name :

Kapoor and Parekh Associates

Chartered Accountant

 

 

Subsidiaries :

  • Ajanta Pharma (Mauritius) Limited
  • Ajanta Pharma Inc, USA
  • Ajanta Pharma Philippines Inc
  •  

 

 

Associates :

  • Turkmendarman Ajanta Pharma Limited
  • Gencrest Limited

 

CAPITAL STRUCTURE

 

AS ON 31.03.2010

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

1,50,00,000

Equity Shares

Rs.10/- each

Rs. 150.000 Millions

1,50,00,000

Preference Shares

Rs.10/- each

Rs. 150.000 Millions

 

 

 

 

 

Total

 

Rs. 300.000 Millions

 

Issued Capital,:

No. of Shares

Type

Value

Amount

 

 

 

 

1,18,61,800

Equity Shares

Rs.10/- each

Rs. 118.618 Millions

 

 

 

 

 

Subscribed & Paid-up Capital

No. of Shares

Type

Value

Amount

 

 

 

 

1,17,08,500

Equity Shares

Rs.10/- each

Rs. 117.085 Millions

1,53,300

Add – Equity Shares Forfeited-Amount Originally Paid up

 

Rs. 0.876 Million

 

 

 

 

 

Total

 

Rs. 117.961 Millions

 

Notes

 

Of the above Equity Shares :

 

- 12,33,000 Equity Shares are allotted as Bonus Shares by way of capitalisation of reserves.

 

- 31,25,000 Equity Shares were allotted pursuant to Scheme of Amalgamation without payment being received in cash

 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2010

31.03.2009

31.03.2008

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

117.961

117.961

117.961

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

1641.107

1403.516

1223.989

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

1759.068

1521.477

1341.950

LOAN FUNDS

 

 

 

1] Secured Loans

1815.244

2008.558

1330.650

2] Unsecured Loans

217.665

393.661

319.995

TOTAL BORROWING

2032.909

2402.219

1650.645

DEFERRED TAX LIABILITIES

58.009

7.502

0.000

 

 

 

 

TOTAL

3849.986

3931.198

2992.595

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

1608.518

1301.883

938.861

Capital work-in-progress

469.911

551.679

238.802

 

 

 

 

INVESTMENT

170.514

170.514

167.217

DEFERREX TAX ASSETS

0.000

0.000

29.257

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

1051.613

989.801

910.954

 

Sundry Debtors

855.041

969.185

831.314

 

Cash & Bank Balances

52.339

73.107

49.085

 

Other Current Assets

0.000

0.000

0.000

 

Loans & Advances

384.844

402.934

301.174

Total Current Assets

2343.837

2435.027

2092.527

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

665.901

469.938

387.124

 

Other Current Liabilities

0.730

0.529

0.439

 

Provisions

76.163

57.438

86.506

Total Current Liabilities

742.794

527.905

474.069

Net Current Assets

1601.043

1907.122

1618.458

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

3849.986

3931.198

2992.595

 

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2010

31.03.2009

31.03.2008

 

SALES

 

 

 

 

 

Income

3816.685

3194.767

2851.298

 

 

Other Income

12.735

13.764

7.708

 

 

TOTAL                                     (A)

3829.420

3208.531

2859.006

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Materials

1549.268

1276.425

1384.986

 

 

Personnel Expenses

509.096

404.571

289.431

 

 

Other Expenses

1046.081

916.341

717.557

 

 

TOTAL                                     (B)

3104.445

2597.337

2391.974

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)     (C)

724.975

611.194

467.032

 

 

 

 

 

Less

FINANCIAL EXPENSES                                    (D)

190.808

220.305

150.896

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

534.167

390.889

316.136

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

197.556

131.476

69.708

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                              (G)

336.611

259.413

246.428

 

 

 

 

 

Less

TAX                                                                  (I)

51.234

45.640

68.498

 

 

 

 

 

 

PROFIT AFTER TAX (G-I)                                 (J)

285.377

213.773

177.930

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

72.383

82.856

57.060

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

 

Proposed Dividend on Equity Shares

40.980

29.271

29.271

 

 

Tax on Proposed Dividend

6.806

4.975

4.975

 

 

Transfer to General Reserve

210.000

190.000

117.888

 

BALANCE CARRIED TO THE B/S

99.974

72.383

82.856

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

Export Earnings

2123.682

1693.290

NA

 

 

Freight & Insurance

48.133

46.732

NA

 

 

Technology Transfer Fees

3.541

0.761

NA

 

TOTAL EARNINGS

2175.356

1740.783

NA

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

337.823

364.446

NA

 

 

Capital Goods

17.968

17.478

NA

 

 

Others

9.930

9.629

NA

 

TOTAL IMPORTS

365.721

391.553

NA

 

 

 

 

 

 

Earnings Per Share (Rs.)

24.37

18.26

15.20

 

 

QUARTERLY RESULTS (UNAUDITED)

 

PARTICULARS

 

30.06.2010

(Rs. In Millions)

30.09.2010

(Rs. In Millions)

31.12.2010

(Rs. In Millions)

 

1st Quarter

2nd Quarter

3rd Quarter

Net Sales

982.870

1125.060

1205.050

Total Expenditure

804.300

915.890

977.120

PBIDT (Excl OI)

178.570

209.170

227.930

Other Income

2.050

3.600

6.820

Operating Profit

180.620

212.770

234.750

Interest

43.510

43.520

34.590

Exceptional Items

0.000

0.000

0.000

PBDT

137.110

169.250

200.160

Depreciation

51.210

58.990

62.220

Profit Before Tax

85.900

110.260

137.940

Tax

16.110

9.740

18.450

Provisions and Contingencies

0.000

0.000

0.000

Profit After Tax

69.790

100.520

119.490

Extraordinary Items

0.000

0.000

0.000

Prior Period Expenses

0.000

0.000

0.000

Other Adjustment

0.000

0.0000

0.000

Net Profit

69.79

100.520

119.490

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2010

31.03.2009

31.03.2008

PAT / Total Income

(%)

7.45

6.66

6.22

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

8.81

8.11

8.64

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

8.51

6.94

8.12

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.19

0.17

0.18

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

1.57

1.92

1.58

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

3.15

4.61

4.41

 

LOCAL AGENCY FURTHER INFORMATION

 

Sundry Creditors

Particulars

31.03.2010

(Rs. In Millions)

31.03.2009

(Rs. In Millions)

31.03.2008

(Rs. In Millions)

 

 

 

 

Sundry Creditors

665.901

469.938

387.124

 

Operations

 

An excellent performance for the year, with 33% growth in net profit and 19% in sales reflects the company’s robust business model. Exports constituted 61% of total sales with establishment of the company’s brands in the global markets. Exchange rate movement, though remained the area of concern, was contained through a systematic hedging policy, to avoid adverse impact on profitability. the company was able to contain the interest cost during the year, thanks to better cashflow and cooperation extended by its bankers. Various projects and capital expenditure plans have been completed during the year, which has resulted in higher depreciation cost. Overall, the company has improved on its profitability during the Financial year ended March 31, 2010.

 

FIXED ASSETS

 

  • Land & Site Development
  • Buildings
  • Plant & Machinery
  • Furniture & Fixtures
  • Office
  • Equipments
  • Vehicles
  • Computers

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

 

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.44.04

UK Pound

1

Rs.72.19

Euro

1

Rs.63.40

 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

8

PAID-UP CAPITAL

1~10

7

OPERATING SCALE

1~10

7

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

6

--PROFITABILIRY

1~10

6

--LIQUIDITY

1~10

7

--LEVERAGE

1~10

7

--RESERVES

1~10

7

--CREDIT LINES

1~10

7

--MARGINS

-5~5

-

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

YES

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

62

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.